Claims for Patent: 6,808,922

Summary for Patent: 6,808,922

Title:	Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
Abstract:	A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (\"NOI\"); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (\"NS\") capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.
Inventor(s):	Bebbington; Christopher Robert (Berkshire, GB), Kingsman; Susan Mary (Oxon, GB), Uden; Mark (Oxon, GB), Kingsman; Alan John (Oxon, GB), Mitrophanos; Kyriacos (Oxon, GB)
Assignee:	Oxford Biomedica Limited (Oxford, GB)
Application Number:	09/508,516
Patent Claims:	1. A retroviral vector comprising: (a) a 3' and 5' long terminal repeat (LTR); (b) a functional splice donor site within the 5' LTR; (c) a functional splice donor site; (d) a first nucleotide sequence of interest (NOI) flanked upstream by the functional splice donor site and downstream by the functional splice acceptor site; and (e) a second NOI downstream of the functional slice acceptor site and upstream of the 3' LTR; whereby the first NOI is capable of being spliced out of RNA when transcribed from the retroviral vector. 2. The retroviral vector according to claim 1 wherein the second NOI encodes a therapeutic expression product. 3. The retroviral vector according to claim 1 wherein the first NOI, or an expression product thereof, comprises a selectable marker or a viral element. 4. The retroviral vector according to claim 1 wherein the functional splice donor site is from a virus. 5. The retroviral vector according to claim 1 wherein the functional splice donor site is from an intron. 6. The retroviral vector according to claim 5 wherein the intron is the small t-intron of SV40 virus. 7. The retroviral vector according to claim 1 further comprising a multiple cloning site, wherein the functional splice acceptor site is locate upstream of the multiple cloning site. 8. The retroviral vector according to claim 1 wherein the functional splice acceptor site is from a nucleotide sequence coding for an immunological protein. 9. The retroviral vector according to claim 8 wherein the immunological protein is an immunoglobulin. 10. Tho retroviral vector according to claim 9 wherein the immunoglobulin is from an immunoglobulin heavy chain variable region. 11. The retroviral vector according to claim 1 wherein the vector is a murine oncoretrovirus vector or a lentivirus vector. 12. The retroviral vector according to claim 11 wherein the vector is a MMLV, MSV, MMTV, HlV-1 or EIAV retroviral vector. 13. A method of producing a retroviral vector comprising a functional splice donor site within its 5' long terminal repeat (LTR), the method comprising: (a) introducing, into a packaging cell, a retroviral pro-vector comprising: (i) a 3' and 5' L' LTR; (ii) a functional splice donor site located within the 3' LTR; (iii) a functional splice acceptor site upstream of the splice donor site; (iv) a first nucleotide sequence of interest (NOI) upstream of the functional splice acceptor site, wherein the first NOI comprises a packaging signal; and (v) a second NOI downstream of the functional splice acceptor site and upstream of the 3' LTR, wherein the retroviral pro-vector is packaged into a viral particle in the packaging cell; and (b) infecting a target cell with the viral particle, wherein the retroviral pro-vector is reverse transcribe; thereby producing a retroviral vector comprising a functional splice donor site within its 5' LTR. 14. The method according to claim 13 wherein the first NOI is expressed in the packaging cell. 15. The method according to claim 13 wherein the first NOI further comprises a selectable marker or a viral element. 16. The method according to claim 15 wherein the viral element is a retroviral envelope sequence. 17. The method according to claim 13 wherein the retroviral pro-vector is a murine oncoretrovirus pro-vector or a lentivirus retroviral pro-vector. 18. The method according to claim 17 wherein the retroviral pro-vector is a MMLV, MSV, MMTV, HIV-1, or EIAV retroviral pro-vector. 19. The method according to claim 13 wherein the retroviral pro-vector comprises a non-retroviral transcriptional control sequence upstream of the functional splice donor site. 20. The method according to claim 19, wherein the transcriptional control sequence is an internal promoter. 21. The method according to claim 19, wherein the transcriptional control sequence is located in the 5' LTR. 22. The method according to claim 19, wherein the transcriptional control sequence is located in the 3' LTR. 23. A retroviral vector comprising a functional splice donor site with its 5' LTR, wherein the retroviral vector is produced by the method of claim 13. 24. A retroviral vector comprising: (a) a 3' and 5' long terminal repeat (LTR); (b) a functional splice donor site located within the 5' LTR; (c) a functional splice acceptor site located downstream of the functional splice donor site; and (d) an NOI downstream of the functional splice acceptor site and upstream of the 3' LTR; whereby an intervening sequence between the functional splice donor site and the functional splice acceptor site spliced out of RNA transcribe from the retroviral vector. 25. The retroviral vector according to claim 24, wherein the intervening sequence comprises a viral element. 26. The retroviral vector according to claim 25, wherein the viral element is a package signal. 27. The retroviral vector according to claim 24, wherein the functional splice donor site is from a virus. 28. The retroviral vector according to claim 24, wherein the functional splice donor site is from an intron. 29. The retroviral vector according to claim 28, wherein the intron is the small t-intron of SV40 virus. 30. The retroviral vector according to claim 24, wherein the comprising a multiple cloning site, wherein the functional splice acceptor site is located upstream of the multiple cloning site. 31. The retroviral vector according to claim 24, wherein the functional splice acceptor site is from a nucleotide sequence coding for an immunological protein. 32. The retroviral vector according to claim 31, wherein the immunological protein is an immunoglobulin. 33. The retroviral vector according to claim 32, wherein the immunoglobulin is from an immunoglobulin heavy chain variable region. 34. The retroviral vector according to claim 24, wherein the vector is a murine oncoretrovirus vector or a lentivirus vector. 35. The retroviral vector according to claim 34, wherein the vector is a MMLV, MSV, MMTV, HIV-1 or EIAV retroviral vector. 36. A method of producing a retroviral vector comprising a functional splice donor site within its 5' LTR, the method comprising: (a) introducing into a packaging cell, a retroviral pro-vector comprising: (i) a 3' and 5' LTR; (ii) a functional splice donor site located within the 3' LTR; (iii) a functional splice acceptor site; (iv) a packaging signal upstream of the functional splice acceptor site; and (v) an NOI downstream of the functional splice acceptor site and upstream of the 3' LTR, wherein the retroviral pro-vector is packaged into a viral particle in the packaging cell; and (b) infecting a target cell with the viral particle, wherein the retroviral pro-vector is reverse transcribed; thereby producing a retroviral vector comprising a functional splice donor site within its 5' LTR. 37. The method according to claim 36, wherein the retroviral pro-vector comprises a non-retroviral transcriptional control sequence upstream of the functional splice donor site. 38. The method according to claim 37, wherein the transcriptional control sequence is an internal promoter. 39. The method according to claim 37, wherein the transcriptional control sequence is located in the 5' LTR. 40. The method according to claim 37, wherein the transcriptional control sequence is located in the 3' LTR. 41. A retroviral vector comprising a functional splice donor site within its 5' LTR, wherein the retroviral vector is produced by the method of claim 36.

Details for Patent 6,808,922

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-09-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-09-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-09-25